Opus Genetics, Inc.
$5.54
▼
-2.99%
2026-04-21 07:35:00
opusgtx.com
NCM: IRD
Explore Opus Genetics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$394.17 M
Current Price
$5.54
52W High / Low
$5.81 / $0.71
Stock P/E
—
Book Value
$0.22
Dividend Yield
—
ROCE
-90.9%
ROE
-2.42%
Face Value
—
EPS
$-0.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
27
Beta
0.52
Debt / Equity
7.36
Current Ratio
6.43
Quick Ratio
6.43
Forward P/E
-9.43
Price / Sales
26.86
Enterprise Value
$337.4 M
EV / EBITDA
-8.75
EV / Revenue
23.77
Rating
Strong Buy
Target Price
$9.93
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zevra Therapeutics, Inc. | $10.78 | 7.23 | $601.51 M | — | -1.72% | 85.66% | $13.16 / $6.85 | $2.72 |
| 2. | Pluri Inc. | $3.59 | — | $36.08 M | — | -348.95% | 669.52% | $7.13 / $2.82 | $-1.46 |
| 3. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 4. | Viridian Therapeutics, Inc. | $14.68 | — | $1.5 B | — | -43.85% | -49.16% | $34.29 / $11.76 | $5.79 |
| 5. | Clearmind Medicine Inc. | $1.14 | — | $2.38 M | — | -475.2% | -1.2% | $52.4 / $0.59 | $5.49 |
| 6. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
| 7. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.87 M | 3.08 M | 2.88 M | 4.37 M | 4.3 M | — |
| Operating Profit | -11.45 M | -8.31 M | -8.91 M | -9.93 M | -10.03 M | — |
| Net Profit | -16.52 M | -17.45 M | -7.42 M | -8.19 M | -35.13 M | — |
| EPS in Rs | -0.23 | -0.25 | -0.1 | -0.12 | -0.49 | -0.29 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 14.2 M | 10.99 M | 19.05 M | 39.85 M |
| Operating Profit | -38.6 M | -34.07 M | -10.56 M | 18.23 M |
| Net Profit | -49.59 M | -57.53 M | -9.99 M | 17.89 M |
| EPS in Rs | -0.7 | -0.81 | -0.14 | 0.25 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 50.24 M | 36.86 M | 53.95 M | 48.99 M |
| Total Liabilities | 34.9 M | 30.14 M | 4.04 M | 2.75 M |
| Equity | 15.35 M | 6.72 M | 49.91 M | 46.24 M |
| Current Assets | 50.04 M | 36.61 M | 53.95 M | 48.99 M |
| Current Liabilities | 7.78 M | 11.29 M | 4.04 M | 2.75 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -35.25 M | -25.58 M | -1.11 M | 14.31 M |
| Investing CF | 0 M | 1.21 M | 0 M | 0 M |
| Financing CF | 50.02 M | 4.19 M | 8.98 M | 3.79 M |
| Free CF | -35.25 M | -25.58 M | -1.11 M | 14.31 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -42.3% | -52.2% | — | — |
| Earnings Growth % | -476.13% | -155.83% | — | — |
| Profit Margin % | -523.4% | -52.42% | 44.89% | — |
| Operating Margin % | -309.99% | -55.45% | 45.74% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -523.31% | -45.36% | 45.71% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.